



To: Medical Staff, House staff, Nursing Staff, Patient Care Centers, and Outpatient Clinics

From: Clarence Chan, MD, PhD
Assistant Professor, Department of Pathology
Associate Medical Director, Hyde Park Clinical Chemistry and Laboratory Informatics

Date: 2/11/2026

Subject: Preeclampsia Risk Assessment (sFlt-1/PIGF Ratio) Method Change at UCM Clinical Chemistry Lab - Hyde Park

Effective Date: 2/18/2026

Laboratory Section: Chemistry

Summary:

Effective February 18, 2026, the Hyde Park Clinical Chemistry Laboratory will transition its preeclampsia risk assessment testing from the Thermo Fisher Kryptor sFlt-1/PIGF assay **to the Roche sFlt-1/PIGF assay**. Both assays are FDA approved for clinical use as a prognostic aid for risk assessment in pregnant women with a singleton pregnancy (23+0 to 34+6/7 weeks' gestation) who are hospitalized for hypertensive disorders of pregnancy, to assess the risk of developing preeclampsia with severe features within 2 weeks of testing. The sFlt-1/PIGF risk assessment ratio is highly concordant between the two methods, ensuring consistent clinical interpretation and patient management.

Among patients hospitalized for hypertensive disorders of pregnancy:

- 95% of patients with an sFlt-1/PIGF ratio **below 39** (using the new Roche assay) **did not** develop preeclampsia with severe features within 2 weeks, whereas
- 67% of patients with a ratio of **39 or greater did** develop preeclampsia with severe features within 2 weeks.

Clinicians can continue to rely on these risk assessment results to help guide patient care decisions.

Test Information:

Test Name [Procedure] (Code): Preeclampsia sFlt-1/PIGF Ratio [LABCHPECRA] (850033)

Availability: 24 hours/day, 7 days/week

Acceptable Specimen Types: Serum (red-top tubes)

Reference Range: <39

This new assay will be performed on the automated chemistry line, allowing for random-access, 24/7 testing and significantly faster turnaround times due to automation. Please note the change in acceptable specimen type to red-top, gel-free serum tubes only, as well as the reference range change from <40 for the current assay to <39 for the new assay.

For questions or further details, please contact:

- The UCM Clinical Chemistry Lab – Hyde Park at 773-702-1772.
- Clarence Chan, MD, PhD, Associate Medical Director, Clinical Chemistry Service clarence.chan@bsd.uchicago.edu
- Vishnu Samara, PhD, Assistant Medical Director, Clinical Chemistry Service vsamara@bsd.uchicago.edu
- Melissa S Pessin, MD, PhD, Interim Medical Director, Clinical Chemistry Service pessinm@bsd.uchicago.edu